Pegfilgrastim-induced hyperleukocytosis

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1524-1530

  Snyder, Ronald L ^a   Stringham, Delevan J ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Filgrastim; Hyperleukocytosis; Neutropenia; Pediatrics; Pegfilgrastim

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FOLINIC ACID; MESNA; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG CLEARANCE; DRUG MECHANISM; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MEDULLOBLASTOMA; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHILD, PRESCHOOL; FILGRASTIM; HUMANS; LEUKOCYTES; LEUKOCYTOSIS; MALE; MEDULLOBLASTOMA; NEUTROPENIA;

EID: 34548253362     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K093     Document Type: Article

References (35)

1. Bodey GP, Buckely M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Li Y, Karlin A, Loike JD, Silverstein SC. A critical concentration of neutrophils is required for effective bacterial killing in suspension. Proc Natl Acad Sci U S A 2002;99:8289-94.
3. National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/ reporting/ctc_v30.html. Publish date August 9, 2006 (accessed 2006 Sep 21).
4. Bonadonna G, Valgusso P. Dose-response effect of chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
5. Package insert. Neulasta (pegfilgrastim). Thousand Oaks, CA: Amgen, September 15, 2005.
6. Lyman GH, Kuderere NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002;62(suppl 1):65-78.
7. Fortner BV, Okon TA, Zhu L, et al. Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice. Commun Oncol 2004;1:23-8.
8. Package insert. Neupogen (filgrastim). Thousand Oaks, CA: Amgen, December 20, 2004.
9. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects of normal and leukemic myeloid cells. Science 1986;232:61-5.
10. Hollingshead LM, Goa KI. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991;42:300-30.
11. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994;48:731-60.
12. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. J Clin Oncol 2006;19:3187-205.
13. Levine JE, Laurence A. Clinical applications of hematopoietic growth factors in pediatric oncology. Opin Hematol 2002;9:222-7.
14. Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 2005;5:1635-46.
15. Roskos LK, Yang B, Schwab G, et al. A cytokinetic model of r-metHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the 'self-regulation' of SD/01 elimination in non-small cell lung cancer (NSCLC) patients (abstract 2085). In: Proceedings of American Society of Hematology, 1998;92:507A.
16. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8.
17. Holmes FA, Jones SE, O'Shaughnessy J, et al. Once-per-cycle pegylated filgrastim (SD/01) is as effective and safe as daily filgrastim in reducing chemotherapy-induced neutropenia over multiple cycles of therapy (abstract 355). Presented at: 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-9, 2000.
18. Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol 2005;27:449-51.
19. te Poele EM, Kamps WA, Tamminga RYJ, Leeuw JA, Postma A, de Bont ESJM. Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol 2005;27:627-9.
20. Andre N, Kababri ME, Bertrand P, et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 2007;18:277-81.
21. Spunt SL, Sender L, Santana VM. Pegfilgrastim in pediatric patients with sarcoma receiving intensive chemotherapy (abstract 1656). Pediatr Res 2003;53:290A.
22. Koontz SE, Mohassel LR, Jaffe N, et al. Safety and efficacy of pegfilgrastim in pediatric oncology patients: the MD Anderson Cancer Center experience (abstract 8272). Am Soc Clin Oncol 200423:792.
23. Layton JE. Evidence for a novel in vivo control mechanism for granulopoesis: mature cell control of a regulatory growth factor. Blood 1989;74:1303-7.
24. Stute N, Santana VM, Rodman JH, Schell MJ, Ihie JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992;11:2849-54.
25. Kearns CM, Wang WC, Stute N, Ihie JN, Evans WE. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J Pediatr 1993;123:471-9.
26. Grigg AP. A comparison of pegfilgrastim and filgrastim. Clin Adv Hematol Oncol 2005;3:176-80.
27. Roskos LK, Yang B, Schwab G, Lockbaum P, Molineux G, Khoo K. A cytokinetic model describes the granulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteers (abstract PIII-81). Clin Pharmacol Ther 1999;65:196.
28. Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003;23:9s-14s.
29. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
30. McCance KL. Structure and function of the hematologic system. In: Pathophysiology: the biologic basis for disease in adults and children. 4th ed. St. Louis, MO: Mosby, 2002:811-42.
31. Holland SM, Gallin JI. Disorders of granulocytes and monocytes. In: Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill, 2002:349-58.
32. Holland SM, Gallin JL Disorders of granulocytes and monocytes. 2006. Harrison's Online. www.accessmedicine.com/resourceToc.aspx?resourceID=4 (accessed 2006 Oct 2).
33. Rheingold SR, Lange BJ. Oncologic emergencies. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:1177-203.
34. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
35. Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology definition, and alternative treatment approaches. Clin Adv Hematol Oncol 2005;3:54-61.